AIM ImmunoTech Inc. (NYSE:AIM) stock is down -7.00% to close at $1.86 on Wednesday, 03/25/20. AIM stock is lower by -$0.14 from the previous closing price of $2.00 on volume of 3475209 shares. In the meantime, AIM was trading in the Healthcare sector, the stock is trading -87.44% low as compared to its 52-week high price and 388.19% high as compared to its 52-week low price. Of example, both the price and the high and low measurements of 52 weeks will give you a clear image for determining the price track. The firm has a Weighted Alpha of -65.7. A positive weighted alpha shows that over the past year the stock has risen. A negative means that over the same period the stock is down.What do the Analysts Think?
Over the last 12 months, AIM ImmunoTech Inc. (AIM) stock has fallen by -73.18 percent, and Wall Street analysts’ average rating is a Buy. AIM stock has an average target price of $3.83 in addition to the average rating from Wall Street analysts. This suggests investors foresee the inventory in the next 12 months to benefit 51.44%.EPS Growth and Stock Performance
AIM ImmunoTech Inc. also currently has an EPS Growth of 22.90 percent for current year, showing analysts have bullish about their potential for near-term earnings. EPS is expected to reach 25.00 percent over the next five years, while EPS growth was 28.20 percent over the past five years, along with sales growth of 19.60 percent over the past five years. Next year’s EPS growth is estimated at 67.30%.
The performance of the stocks typically measures, how much a stock gain or lose its value during different time spans. AIM ImmunoTech Inc. (NYSE:AIM) has achieved around 77.14% in the last 30 days and around 301.21% over the last three months. The stock exposed return of -99.86% over the period of last 5 years and recorded return of -21.19% over a week. In the last 6 months, the stock has been observed at 26.53% return.Tracking the Profitability and Valuation Ratios
As of the last trading session the stock has achieved a market cap of $54.70M. Market capitalization is the cumulative dollar value of all of a company’s outstanding shares and is used to quantify businesses and consider their overall market value. The stock has attained Price-to-sales ratio of 182.34 replicates the cost to be found on sales by the market. The firm maintained Price-to-book ratio of 0.37, which is used to equate the market value of a stock with its book value.How Insiders are Trading the Stock?
Mostly, the investors and traders are looking for stocks with the high ownership of company’s management because they think that when the company’s management is the major shareholder of a firm, the management will run the business for itself and they will never act those activities which are against their interests and they will always try to create shareholder value in the long-term. Currently, 1.60% of AIM ImmunoTech Inc.‘s shares possessed by insiders, while 2.20% shares possessed by financial institutions.